Study of MHB088C for Patients With Advanced Solid Malignant Tumors
A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
Study of MHB088C for Patients With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT07102004 by Qilu Pharmaceutical Co., Ltd., with 515 participants planned, started 2023-06-20 and due to reach its primary completion in 2026-07. Interventions recorded: MHB088C for Injection.
Similar pages
not linked directly; found by shared links- TrialGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Shares QLC5508, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Shares QLC5508, Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Shares Qilu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase II Study of QLC2519 in Pediatric Solid Tumor Participants
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialA Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Shares QLC5508, Qilu Pharmaceutical.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.